NSAIDs relieve osteoarthritis (OA) pain, but cardiovascular safety in question even for diclofenac, ibuprofen, naproxen, and celecoxib: what are the alternatives?

NSAIDs relieve osteoarthritis (OA) pain, but cardiovascular safety in question even for... Citing the excellent editorial comment by Pekka Mäntyselkä 10 years ago in PAIN on the “Balancing act with geriatric pain treatment”, World Health Organisation predicts that there will be 1.2 billion people above 60 years by 2025, 2 billion by 2050, and in the developed world the very old, aged 80+, is the fastest growing population group. Persistent pain, due to degenerative diseases, osteoarthritis (OA) in particular, becomes more prevalent as a person ages [1]. Comorbidities and polypharmacies increasingly pose dilemmas with increasing risks of interactions and serious side effects. Pain and dysfunction from OA are poorly relieved [2], but NSAIDs (traditional tNSAIDs and COX-2 specific inhibitors – COX- IBs) are still recommended as cornerstones in the pharmacological treatment of OA [3].In this issue of the Scandinavian Journal of Pain Patricia Guyot and her co-workers with senior author Andrew Moore, publish an interesting network meta-analysis of diclofenac, ibuprofen, naproxen, indomethacine, and piroxicam for osteoarthritis pain [4]. They analyzed data from 29 previously unpublished randomized, controlled (double-blind) trials (RCTs) from the time before the specific COX- 2-inhibitors appeared and before cardiovascular risks of traditional NSAIDs and the COXIBs were recognized.A network meta-analysis is possible when one drug is compare with http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Scandinavian Journal of Pain de Gruyter

NSAIDs relieve osteoarthritis (OA) pain, but cardiovascular safety in question even for diclofenac, ibuprofen, naproxen, and celecoxib: what are the alternatives?

Loading next page...
 
/lp/degruyter/nsaids-relieve-osteoarthritis-oa-pain-but-cardiovascular-safety-in-nqXyEdMQr0
Publisher
De Gruyter
Copyright
© 2017 Scandinavian Association for the Study of Pain
ISSN
1877-8860
eISSN
1877-8879
D.O.I.
10.1016/j.sjpain.2017.05.009
Publisher site
See Article on Publisher Site

Abstract

Citing the excellent editorial comment by Pekka Mäntyselkä 10 years ago in PAIN on the “Balancing act with geriatric pain treatment”, World Health Organisation predicts that there will be 1.2 billion people above 60 years by 2025, 2 billion by 2050, and in the developed world the very old, aged 80+, is the fastest growing population group. Persistent pain, due to degenerative diseases, osteoarthritis (OA) in particular, becomes more prevalent as a person ages [1]. Comorbidities and polypharmacies increasingly pose dilemmas with increasing risks of interactions and serious side effects. Pain and dysfunction from OA are poorly relieved [2], but NSAIDs (traditional tNSAIDs and COX-2 specific inhibitors – COX- IBs) are still recommended as cornerstones in the pharmacological treatment of OA [3].In this issue of the Scandinavian Journal of Pain Patricia Guyot and her co-workers with senior author Andrew Moore, publish an interesting network meta-analysis of diclofenac, ibuprofen, naproxen, indomethacine, and piroxicam for osteoarthritis pain [4]. They analyzed data from 29 previously unpublished randomized, controlled (double-blind) trials (RCTs) from the time before the specific COX- 2-inhibitors appeared and before cardiovascular risks of traditional NSAIDs and the COXIBs were recognized.A network meta-analysis is possible when one drug is compare with

Journal

Scandinavian Journal of Painde Gruyter

Published: Dec 29, 2017

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial